9C3V
Crystal structure of GDP-bound KRAS G12D/D54R: Suppressing G12D oncogenicity via second-site D54R mutation
Summary for 9C3V
| Entry DOI | 10.2210/pdb9c3v/pdb |
| Descriptor | Isoform 2B of GTPase KRas, GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, ... (5 entities in total) |
| Functional Keywords | kras, ras, nucleotide-binding protein, signaling protein, g12d, d54r, oncoprotein |
| Biological source | Homo sapiens (human) |
| Total number of polymer chains | 2 |
| Total formula weight | 39888.98 |
| Authors | |
| Primary citation | Kwon, J.J.,Dilly, J.,Liu, S.,Kim, E.,Bian, Y.,Dharmaiah, S.,Tran, T.H.,Kapner, K.S.,Ly, S.H.,Yang, X.,Rabara, D.,Waybright, T.J.,Giacomelli, A.O.,Hong, A.L.,Misek, S.,Wang, B.,Ravi, A.,Doench, J.G.,Beroukhim, R.,Lemke, C.T.,Haigis, K.M.,Esposito, D.,Root, D.E.,Nissley, D.V.,Stephen, A.G.,McCormick, F.,Simanshu, D.K.,Hahn, W.C.,Aguirre, A.J. Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity. Biorxiv, 2024 Cited by PubMed Abstract: To dissect variant-function relationships in the KRAS oncoprotein, we performed deep mutational scanning (DMS) screens for both wild-type and KRAS mutant alleles. We defined the spectrum of oncogenic potential for nearly all possible variants, identifying several novel transforming alleles and elucidating a model to describe the frequency of mutations in human cancer as a function of transforming potential, mutational probability, and tissue-specific mutational signatures. Biochemical and structural analyses of variants identified in a KRAS second-site suppressor DMS screen revealed that attenuation of oncogenic KRAS can be mediated by protein instability and conformational rigidity, resulting in reduced binding affinity to effector proteins, such as RAF and PI3-kinases, or reduced SOS-mediated nucleotide exchange activity. These studies define the landscape of single amino acid alterations that modulate the function of KRAS, providing a resource for the clinical interpretation of KRAS variants and elucidating mechanisms of oncogenic KRAS inactivation for therapeutic exploitation. PubMed: 39484452DOI: 10.1101/2024.10.22.618529 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.51 Å) |
Structure validation
Download full validation report
